Review
Cardiac & Cardiovascular Systems
Edoardo Bertero, Jan Dudek, Clement Cochain, Murilo Delgobo, Gustavo Ramos, Brenda Gerull, Takahiro Higuchi, Martin Vaeth, Alma Zernecke, Stefan Frantz, Ulrich Hofmann, Christoph Maack
Summary: The interplay between the cardiovascular system, metabolism, and inflammation plays a central role in the pathophysiology of cardiovascular diseases. This paper provides an overview of the interrelation between inflammation and metabolism, discusses the involvement of disrupted immuno-metabolic interface in cardiovascular disease, and presents new technologies and therapeutic approaches.
CARDIOVASCULAR RESEARCH
(2022)
Article
Plant Sciences
Jingyu Ni, Zhihao Liu, Miaomiao Jiang, Lan Li, Jie Deng, Xiaodan Wang, Jing Su, Yan Zhu, Feng He, Jingyuan Mao, Xiumei Gao, Guanwei Fan
Summary: This study confirms the protective effect of ginsenoside Rg3 on heart function in TAC-induced heart failure mice and reveals the molecular mechanisms involved in regulating glucose metabolism and improving insulin resistance.
JOURNAL OF GINSENG RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Hui Ye, Yanan He, Chuan Zheng, Fang Wang, Ming Yang, Junzhi Lin, Runchun Xu, Dingkun Zhang
Summary: Type 2 diabetes mellitus (T2DM) and heart failure (HF) are diseases with high morbidity and mortality. Their combination is common in middle-aged and elderly individuals, making treatment challenging. Abnormal insulin signaling pathway, a common pathogenic mechanism, could serve as a specific target for the treatment of T2DM patients with HF.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Karen Lambert, Marie Demion, Jean-Christophe Lagace, Marie Hokayem, Mamta Dass, Anne Virsolvy, Bernard Jover, Annick Bourret, Catherine Bisbal
Summary: The study found that exercise and polyphenols can prevent cardiac hypertrophy, but their combination does not bring additional benefits. Rats supplemented with polyphenols showed a shift from pathologic to physiological hypertrophy. Polyphenols supplementation appears to have a better protective effect in sedentary obese insulin-resistant rats compared to exercised rats.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2021)
Review
Biochemistry & Molecular Biology
Emilie Dubois-Deruy, Yara El Masri, Annie Turkieh, Philippe Amouyel, Florence Pinet, Jean-Sebastien Annicotte
Summary: Lysine acetylation is a conserved mechanism that affects various biological processes, and its dysregulation is associated with cardiac dysfunction. This review summarizes the regulation of cardiac acetylation and its roles in both physiological and pathological conditions, highlighting its importance in cardiovascular diseases and suggesting KATs and KDACs as potential therapeutic targets for heart failure.
Review
Immunology
Hamid Aria, Marzieh Rezaei, Shima Nazem, Abdolreza Daraei, Ghasem Nikfar, Behnam Mansoori, Maryam Bahmanyar, Alireza Tavassoli, Mohammad Kazem Vakil, Yaser Mansoori
Summary: ATP and other nucleoside phosphates, through purinergic receptors and ectonucleotidases, play a crucial role in regulating signaling pathways in the tumor microenvironment. They affect tumor cell metabolism and contribute to therapy resistance.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Daniela Sorriento, Maria Rosaria Rusciano, Valeria Visco, Antonella Fiordelisi, Federica Andrea Cerasuolo, Paolo Poggio, Michele Ciccarelli, Guido Iaccarino
Summary: Insulin resistance is a pathophysiological condition associated with obesity, glucose intolerance, dyslipidemia, and hypertension, leading to type 2 diabetes and cardiovascular diseases. Studies have identified G Protein Coupled Receptor Kinase type 2 (GRK2) as a potential therapeutic target for insulin resistance and its associated phenotypes.
Article
Biochemistry & Molecular Biology
Frank Yu, Bianca McLean, Mitesh Badiwala, Filio Billia
Summary: Cardiovascular disease is the leading cause of mortality globally, with heart failure affecting millions of people. The use of metabolomics and lipidomics has improved our understanding of heart failure and revealed new pathways and potential interventions. The discovery of metabolic effects of heart failure drugs, particularly sodium-glucose transport protein 2 inhibitors, has revolutionized the treatment of heart failure.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Urology & Nephrology
Nikayla Patel, Muhammad Magdi Yaqoob, Dunja Aksentijevic
Summary: Chronic kidney disease is associated with an increased risk of cardiovascular disease, such as heart failure. Understanding the metabolic remodeling of the heart in chronic kidney disease can help develop new treatments for cardiac complications.
NATURE REVIEWS NEPHROLOGY
(2022)
Article
Multidisciplinary Sciences
Sang R. Lee, Jun H. Heo, Seong Lae Jo, Globinna Kim, Su Jung Kim, Hyun Ju Yoo, Kyu-Pil Lee, Hyo-Jung Kwun, Hyun-Jin Shin, In-Jeoung Baek, Eui-Ju Hong
Summary: Pgrmc1 plays a crucial role in the heart, with its absence leading to high levels of fat and reduced mitochondrial DNA copies. Additionally, the lack of Pgrmc1 results in decreased fatty acid oxidation activity in the heart, particularly under high-fat diet conditions, making the heart more susceptible to lipotoxicity.
SCIENTIFIC REPORTS
(2021)
Review
Biochemistry & Molecular Biology
Alexandrine Bertaud, Ahmad Joshkon, Xavier Heim, Richard Bachelier, Nathalie Bardin, Aurelie S. Leroyer, Marcel Blot-Chabaud
Summary: Cardiac fibrosis is a condition characterized by irreversible necrosis of the heart muscle, caused by various acute or chronic diseases, genetic alterations, or aging. Currently, there is no curative treatment available to prevent or attenuate cardiac fibrosis, which leads to progressive cardiac dysfunction and life-threatening outcomes. This review summarizes different targets and new strategies proposed to fight cardiac fibrosis, as well as discussing future directions, such as the use of exosomes or nanoparticles.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Yudi Zhang, Yuping Fu, Tiannan Jiang, Binghua Liu, Hongke Sun, Ying Zhang, Boyuan Fan, Xiaoli Li, Xinghua Qin, Qiangsun Zheng
Summary: The study found that promoting fatty acid oxidation via L-carnitine could reduce obesity-related atrial fibrillation susceptibility in mice, alleviating atrial structural remodeling. The research revealed that enhancing fatty acid oxidation may be a potential therapeutic target for preventing and treating atrial fibrillation by activating the AMPK signaling pathway and reducing atrial lipotoxicity.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Mingzhou Jiang, Xi Fan, Yiqing Wang, Xiaotian Sun
Summary: Oxygen is essential for cardiomyocyte metabolism, and hypoxia may lead to metabolic remodeling and heart failure. Hypoxia-inducible factors (HIFs) are implicated in regulating hypoxia-induced metabolic changes and have potential therapeutic implications for heart failure. Understanding the effects of hypoxic pathways on heart failure can provide new treatment options.
EXPERIMENTAL CELL RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Parveen K. Garg, Mary L. Biggs, Jorge R. Kizer, Sanjiv J. Shah, Bruce Psaty, Mercedes Carnethon, John S. Gottdiener, David Siscovick, Kenneth J. Mukamal
Summary: This study evaluated the association between glucose dysregulation and subclinical cardiac dysfunction in an older population. The findings suggest that the relationship between glucose dysregulation and cardiac dysfunction is largely attenuated after adjusting for central adiposity.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Xuewen Duan, Xingguang Liu, Zhenzhen Zhan
Summary: Mortality from heart diseases, especially ischemic cardiomyopathy, remains the highest in the world. While adult mammalian hearts have limited regenerative capacity, early neonatal hearts possess stronger regenerative ability. Promoting endogenous regeneration of adult mammalian cardiomyocytes is crucial for improving the prognosis of heart failure patients and finding effective therapeutic strategies. This review focuses on the role of energy metabolism in cardiac regeneration to provide insights into manipulating heart regeneration and promoting heart repair after injury.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Surgery
Thomas Muhlbacher, Silvio Nadalin, Karina Althaus, Andreas L. Birkenfeld, Nils Heyne, Martina Guthoff
Summary: This study retrospectively analyzed data from our living donor transplantation program over a span of 13 years. It focused on kidney donor candidates who were diagnosed with major medical conditions during the evaluation process. The results showed that among the 436 evaluated candidates, 56% were excluded from donation, and 33.1% of the ineligible candidates were newly diagnosed with a medical condition requiring immediate attention. This highlights the importance of a comprehensive evaluation process in promptly identifying and addressing potential health issues.
CLINICAL TRANSPLANTATION
(2023)
Letter
Gastroenterology & Hepatology
Leontine Sandforth, Nermeen N. EI-Agroudy, Andreas L. Birkenfeld
JOURNAL OF HEPATOLOGY
(2023)
Article
Multidisciplinary Sciences
Kirsten Bucher, Eduardo Rodriguez-Bocanegra, Bernd Wissinger, Torsten Strasser, Simon J. Clark, Andreas L. Birkenfeld, Dorothea Siegel-Axel, M. Dominik Fischer
Summary: AAV vectors produced in different host cells have different immunogenic properties due to the differences in residual host cell components and post-translational modifications. The inflammatory cytokine responses induced by AAV vectors were lot-specific rather than production platform-specific or manufacturer-specific. These responses could be reduced by blocking toll-like receptor 9 signaling or enzymatically reducing DNA using DNase.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Miriam Hoene, Xinjie Zhao, Juergen Machann, Andreas L. L. Birkenfeld, Martin Heni, Andreas Peter, Andreas Niess, Anja Moller, Rainer Lehmann, Guowang Xu, Cora Weigert
Summary: Physical exercise is a powerful preventative measure for cardiometabolic diseases. The individual response to lifestyle interventions varies and cannot currently be predicted. Recent research has shown that Lac-Phe produced during exercise could contribute to weight loss and potentially explain differences in the effectiveness of exercise interventions in humans.
Editorial Material
Cardiac & Cardiovascular Systems
Oliver Schnell, Tadej Battelino, Richard Bergenstal, Andreas L. Birkenfeld, Antonio Ceriello, Alice Cheng, Melanie Davies, Steve Edelman, Thomas Forst, Francesco Giorgino, Jennifer Green, Per-Henrik Groop, Samy Hadjadj, Hiddo J. L. Heerspink, Marcus Hompesch, Baruch Izthak, Linong Ji, Naresh Kanumilli, Boris Mankovsky, Chantal Mathieu, Martin Miszon, Reem Mustafa, Michael Nauck, Roberto Pecoits-Filho, Jeremy Pettus, Kari Ranta, Helena W. Rodbard, Peter Rossing, Lars Ryden, Petra-Maria Schumm-Draeger, Scott D. Solomon, Jan Skrha, Pinar Topsever, Tina Vilsboll, John Wilding, Eberhard Standl
Summary: The 8th Cardiovascular Outcome Trial (CVOT) Summit focused on discussing and exchanging recently completed outcomes trials and key trials important to the cardiovascular field. Topics included the results of trials on heart failure, chronic kidney disease, and obesity, as well as consensus recommendations and guideline updates on diabetes and CKD management. The impact of cardiovascular outcomes on liver disease trials and the role of real-world evidence in confirming trial outcomes were also discussed. The 9th CVOT Summit will be held virtually on November 23-24, 2023.
CARDIOVASCULAR DIABETOLOGY
(2023)
Editorial Material
Cell Biology
Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, Hans-Ulrich Haering, Morris F. White
Summary: Non-alcoholic fatty liver disease (NAFLD) is both a consequence and a cause of insulin resistance and major non-communicable diseases (NCDs). The close relationship between NAFLD and visceral obesity has led to the overshadowing of fatty liver as the main pathomechanism of insulin resistance and NCDs. However, the concept of hepatokines provides a new perspective on the role of the liver in metabolism and offers potential for precision medicine in NAFLD and visceral obesity.
Article
Endocrinology & Metabolism
Carlotta Hoffmann, Peter E. Schwarz, Christos S. Mantzoros, Andreas L. Birkenfeld, Christian Wolfrum, Michele Solimena, Stefan R. Bornstein, Nikolaos Perakakis
Summary: This study aimed to compare the concentrations of GLP-1, glucagon, GIP, and glicentin during an OGTT in patients with different glycemic states. The results showed that hormonal levels did not differ between groups when all subjects were in a prediabetic state. However, one year later, patients progressing to diabetes had lower postprandial increases of glicentin and GLP-1, lower postprandial decrease of glucagon, and higher levels of fasting GIP compared to patients regressing to NGT. Changes in glicentin and GLP-1 were found to be negatively correlated with changes in glucose levels and beta-cell function markers.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Endocrinology & Metabolism
Estela Lorza-Gil, Gabriele Kaiser, Christopher Carlein, Markus D. A. Hoffmann, Gabriele M. Koenig, Sieglinde Haug, Leticia Prates Roma, Elisabeth Rexen Ulven, Trond Ulven, Evi Kostenis, Andreas L. Birkenfeld, Hans-Ulrich Haering, Susanne Ullrich, Felicia Gerst
Summary: Research shows that NEFA plays an important role in the functional maturation and adaptive insulin secretion of neonatal beta cells, with FFA1 being a critical factor. FFA1 promotes insulin secretion and is essential in the adaptation of offspring beta cells to parental high-fat feeding.
Article
Cell Biology
Jennifer Maurer, Xinjie Zhao, Martin Irmler, Anders Gudiksen, Nanna S. Pilmark, Qi Li, Thomas Goj, Johannes Beckers, Martin Hrabe de Angelis, Andreas L. Birkenfeld, Andreas Peter, Rainer Lehmann, Henriette Pilegaard, Kristian Karstoft, Guowang Xu, Cora Weigert
Summary: Metformin treatment leads to lactate production and secretion, as well as reduced glucose consumption. It inhibits respiratory chain complex I and alters cellular redox state, decreasing pyruvate oxidation. These findings suggest that metformin induces dose-dependent lactate production in skeletal muscle by shifting the equilibrium of lactate dehydrogenase reaction.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Article
Endocrinology & Metabolism
Nikolaos Perakakis, Stefan R. Bornstein, Andreas L. Birkenfeld, Andreas Linkermann, Muenevver Demir, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis M. Ruilope, Peter Kolkhof, Robert Lawatscheck, Charlie Scott, George L. Bakris, FIDELIO DKD Investigator, FIGARO DKD Investigator
Summary: This study investigated the effect of finerenone on liver function, cardiovascular, and kidney composite outcomes in patients with chronic kidney disease and type 2 diabetes. The results showed that finerenone had a neutral effect on liver parameters and consistently reduced the risk of kidney composite outcomes. Additionally, it demonstrated significant cardiovascular benefits, even in patients at high risk of developing cardiovascular complications.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Andreas L. Birkenfeld, David Z. I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill
Summary: This study aims to evaluate the efficacy and safety of Finerenone in type 1 diabetes and chronic kidney disease (CKD). Finerenone could potentially become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Endocrinology & Metabolism
Arvid Sandforth, Reiner Jumpertz von Schwartzenberg, Elsa Vazquez Arreola, Robert L. Hanson, Gencer Sancar, Sarah Katzenstein, Karl Lange, Hubert Preissl, Simon Dreher, Cora Weigert, Robert Wagner, Kostantinos Kantartzis, Fritz Schick, Rainer Lehmann, Andreas Peter, Nikoletta Katsouli, Vasilis Ntziachristos, Corinna Dannecker, Louise Fritsche, Nikolaos Perakakis, Martin Heni, Peter Paul Nawroth, Stefan Kopf, Andreas F. H. Pfeiffer, Stefan Kabisch, Michael Stumvoll, Peter E. H. Schwarz, Hans Hauner, Andreas Lechner, Jochen Seissler, Iryna Yurchenko, Andrea Icks, Michele Solimena, Hans-Ulrich Haering, Julia Szendroedi, Annette Schuermann, Martin Hrabe de Angelis, Matthias Blueher, Michael Roden, Stefan R. Bornstein, Norbert Stefan, Andreas Fritcher, Andreas Birkenfeld
Summary: This study investigates the mechanisms of weight loss-induced remission in people with prediabetes. The results suggest that weight loss can improve insulin sensitivity, reduce visceral adipose tissue, and lower the risk of developing type 2 diabetes. The authors propose that remission of prediabetes should be the primary therapeutic aim.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Sijia Zheng, Lina Zhou, Miriam Hoene, Andreas Peter, Andreas L. Birkenfeld, Cora Weigert, Xinyu Liu, Xinjie Zhao, Guowang Xu, Rainer Lehmann
Summary: The gut microbiome plays a significant role in human health and disease, but it is challenging to identify microbiota-associated molecules in human blood or urine. This study used a non-targeted metabolomics approach and found that depletion of the fecal microbiome affected the levels of metabolite ions in urine. The study also annotated 32 compounds associated with the fecal microbiota.
Article
Medicine, General & Internal
Konstantinos Kantartzis, Andreas Fritsche, Andreas L. L. Birkenfeld
Summary: Prediabetes refers to elevated blood glucose levels below the diabetic range, and is often associated with an increased risk of developing diabetes. It is important to identify individuals with prediabetes in order to implement diabetes prevention measures. Structured lifestyle intervention has been proven to be an effective strategy for treating prediabetes.
Article
Urology & Nephrology
Felix Eisinger, Thomas Muehlbacher, Ario Na, Karina Althaus, Silvio Nadalin, Andreas L. Birkenfeld, Nils Heyne, Martina Guthoff
Summary: This study presents a standardized risk-stratified algorithm for induction therapy in kidney transplantation, aiming to balance the risk of rejection and serious infection. After 3 years of implementation, no significant difference was observed in rejection rate and allograft survival among different risk groups. However, patients receiving low-dose alemtuzumab induction therapy had a higher rate of opportunistic fungal infections.
JOURNAL OF NEPHROLOGY
(2023)